Name: 글로벌 시장 동향
SKU: PH2726
Availability: InStock

보고서 요약(국문)

시장 개요
전 세계 경구용 항당뇨병제 시장은 2022년 443억 달러 규모에 달했으며, 2030년까지 808억 달러에 이를 것으로 예상되어 높은 성장세를 보일 전망입니다. 전 세계 경구용 항당뇨병제 시장은 예측 기간(2023-2030년) 동안 연평균 8.0%의 성장률을 기록할 것으로 예상됩니다.
환자의 개별적인 특성, 병력, 치료 목표 등 여러 변수에 따라 제2형 당뇨병 치료에 사용되는 특정 경구용 항당뇨병제는 환자마다 다릅니다. 예를 들어, 카나글리플로진, 다파글리플로진, 엠파글리플로진과 같은 SGLT2 억제제는 신장의 포도당 재흡수를 억제하여 소변으로의 포도당 배설량을 증가시키고 혈당 수치를 낮추는 작용을 합니다.
시장 동향
연구 활동의 증가는 예측 기간 동안 전 세계 경구용 항당뇨병제 시장의 성장을 촉진할 것으로 예상됩니다.

시장 동향 예를 들어, 2022년 12월, 화이자는 G 단백질 결합 수용체(GPCR) 중심의 구조 기반 약물 설계(SBDD) 및 개발 분야의 글로벌 리더인 소세이 그룹(Sosei Group Corporation)에 화이자의 후보 약물 PF-07081532가 2상 임상 시험의 첫 번째 피험자에게 투여되었다고 통보했습니다. 이 목표가 달성되면 소세이 헵타레스(Sosei Heptares)는 1,000만 달러를 받게 됩니다.
차세대 경구용 소분자 GLP-1 수용체 작용제인 PF-07081532는 제2형 당뇨병 및 비만 치료를 위한 1일 1회 복용 약물로 개발되고 있습니다. 화이자는 소세이 헵타레스의 독자적인 StaR(안정화 수용체) 기술을 활용한 다중 표적 연구 협력을 통해 PF-07081532를 발견했습니다. 화이자가 주도한 PF-07081532의 1상 임상 시험은 성공적이었습니다.

인식 제고와 정부 주도의 노력은 예측 기간 동안 전 세계 경구용 항당뇨병제 시장 성장을 촉진하고 있습니다.
세계 최대 규모의 당뇨병 인식 캠페인인 세계 당뇨병의 날은 160개국 이상에서 10억 명이 넘는 사람들에게 영향을 미칩니다. 이 날을 기념하는 주된 목적은 당뇨병에 대한 인식을 높이고 이 주요한 세계적 건강 문제에 대처하기 위한 행동을 장려하는 것입니다. 2021년부터 2023년까지의 세계 당뇨병의 날 캠페인은 "내일을 보호하기 위한 교육"에 초점을 맞추었습니다.
2022년 캠페인은 의료 전문가와 당뇨병 환자를 위한 고품질 당뇨병 교육에 대한 접근성 향상의 필요성을 강조했습니다. 향후 활동은 의료 전문가와 당뇨병 환자의 고품질 당뇨병 교육 접근성 향상의 중요성을 강조할 것입니다.

맞춤형 의약품, 경구용 항당뇨병제 시장 성장 기회 제공
데이터 과학 및 기술의 급속한 발전은 치료 및 예방적 개입의 정확도를 높이고 적절한 환자에게 적절한 시기에 적절한 치료법을 권장할 수 있도록 합니다. 제2형 당뇨병은 복잡하고 이질적이며 다유전자적인 대사 질환이므로 "획일적인" 치료 전략은 효과적이지 않습니다.
유전학, 유전체학, 단백체학 및 대사체학 분야의 기술 발전으로 수천 개의 유전자, 단백질 및 대사 산물을 효율적으로 분석하는 것이 가능해졌습니다. 이는 당뇨병과 같은 다양한 질병 하위 유형과 관련된 유전적 요인 및 유전자 산물을 식별할 수 있는 새로운 기회를 제공합니다.
COVID-19 영향 분석
COVID-19 팬데믹은 경구용 항당뇨병제 시장에 상당한 영향을 미쳤습니다. COVID-19로 인해 환자 행동이 변화했으며, 의료 시설 방문이 감소하고 원격 의료 서비스에 대한 의존도가 증가했습니다. 일부 당뇨병 환자들이 경구용 항당뇨병 약물을 구하는 데 어려움을 겪거나 치료 계획을 제대로 지키지 못했기 때문에 이러한 약물에 대한 수요가 영향을 받았을 수 있습니다.
2023년 현재, 코로나19 상황이 회복되고 모든 의료 시설에서 환자들이 적절한 치료를 받을 수 있게 되면서 전 세계적으로 경구용 항당뇨병 약물에 대한 수요가 증가하고 있습니다.
러시아-우크라이나 분쟁 분석
러시아-우크라이나 전쟁이 경구용 항당뇨병 약물 시장에 미치는 영향은 복잡하고 다면적입니다. 분쟁으로 인해 사람들이 집을 떠나거나 다른 곳으로 피난해야 하므로 인구 이동이 발생할 수 있습니다. 특히 경구용 항당뇨병 약물과 같은 의료 서비스 접근이 어려워 당뇨병 관리에 차질이 생길 수 있습니다. 러시아와 우크라이나 모두 분쟁으로 인해 경제적으로 부정적인 영향을 받았습니다. 개인과 의료 시스템 모두에서 경구용 항당뇨병 약물의 가격과 공급은 경제 불안정, 환율 변동 및 인플레이션 압력의 영향을 받습니다.

시장 세분화 분석
전 세계 경구용 항당뇨병제 시장은 약물 종류, 제형, 유통 채널 및 지역별로 세분화됩니다.
도파민 D2 수용체 작용제 부문은 예측 기간 동안 시장에서 중요한 위치를 차지할 것으로 예상됩니다.
도파민 D2 수용체 작용제 부문은 2022년 경구용 항당뇨병제 시장에서 26.5%의 시장 점유율을 차지했습니다. 본 연구는 브로모크립틴 메실레이트가 혈당 조절을 향상시키는 정확한 기전을 밝혀냈습니다. 아침에 브로모크립틴 메실레이트를 투여하면 혈장 인슐린 농도를 높이지 않고도 제2형 당뇨병 환자의 혈당 조절이 개선되는 것으로 나타났습니다.
이는 속효성 브로모크립틴 제제를 아침에 투여함으로써 말초 에너지 대사(포도당, 지질 대사, 단백질 대사 포함)를 조절하는 뇌 영역에서 중추 도파민 활성이 최고조에 달하는 것과 관련이 있을 수 있습니다.

지리적 분석
주요 업체 간의 협력 및 파트너십 증가와 신제품 출시 증가가 아시아 태평양 지역을 주도하고 있습니다.
아시아 태평양 지역은 경구용 항당뇨병제 시장의 약 24.4%를 차지하며 시장을 선도할 것으로 예상됩니다. 예를 들어, 2022년 1월에는 기존에 주사제로만 사용되던 항당뇨병제가 노보 노디스크 인도(Novo Nordisk India)에 의해 경구용으로 출시되었습니다. 이 회사는 새로운 약물이 제2형 당뇨병 성인 환자의 체중 및 혈당 조절에 도움을 줄 수 있다고 밝혔습니다.
글루카곤 유사 펩타이드 1(GLP-1)이라는 자연 발생 호르몬은 적절한 혈당 수치를 유지하는 데 중요한 역할을 합니다. 펩타이드 및 단백질 기반 생물학적 치료제의 유일한 단점은 정맥 주사로 투여해야 한다는 점이지만, 이러한 치료법은 종종 매우 효과적입니다.

경쟁 환경
주요 글로벌 시장 참여 기업으로는 Glenmark Pharma, Abbott, Biocon, Sanofi S.A., Sunpharma, Novartis, Novo Nordisk, Merck, GlaxoSmithKline, Bristol-Myers Squibb 등이 있습니다.
보고서 구매 이유

• 약물 종류, 복용량, 유통 채널, 지역별 글로벌 경구용 항당뇨병제 시장 세분화를 시각화하고 주요 기업 및 시장 점유율을 파악합니다.

• 시장 동향 및 공동 개발 분석을 통해 사업 기회를 모색합니다.

• 모든 세그먼트를 포함한 경구용 항당뇨병제 시장 수준의 다양한 데이터가 담긴 Excel 데이터 시트를 제공합니다.

• 심층적인 질적 인터뷰와 연구를 바탕으로 종합적인 분석 결과를 담은 PDF 보고서를 제공합니다.

• 주요 기업의 핵심 제품 정보를 담은 Excel 파일 형태의 제품 맵핑을 제공합니다.

본 글로벌 경구용 항당뇨병제 시장 보고서는 약 62개의 표, 61개의 그림, 195페이지 분량으로 구성되어 있습니다.

2023년 목표 고객층
• 제조업체/구매자
• 산업 투자자/투자 은행가
• 시장 조사 전문가
• 신흥 기업

보고서 요약(영어 원문)

Market Overview
The global Oral Anti-Diabetic Drugs Market reached US$ 44.3 billion in 2022 and is projected to witness lucrative growth by reaching up to US$ 80.8 billion by 2030. The global oral anti-diabetic drugs market is expected to exhibit a CAGR of 8.0% during the forecast period (2023-2030).
Based on a number of variables, such as the patient's unique characteristics, medical history, and treatment objectives, the specific oral anti-diabetic medications used in the treatment of type 2 diabetes vary in patients. For instance, SGLT2 inhibitors like canagliflozin, dapagliflozin, and empagliflozin function by preventing the kidneys' reabsorption of glucose, which causes an increase in urine glucose excretion and a decrease in blood sugar levels.
Market Dynamics
The Increasing Research Activities Are Boosting The Global Oral Anti-Diabetic Drugs Market Growth During The Forecast Period.
For instance, in December 2022, Pfizer notified Sosei Group Corporation, a global leader in G protein-coupled receptor (GPCR) focused structure-based drug design (SBDD) and development, that the candidate medicine PF-07081532 from Pfizer has been dosed to the first subject in Phase 2 clinical trial. When this goal is reached, Sosei Heptares will get a payment of $10 million USD.
Next-generation oral small molecule GLP-1 receptor agonist PF-07081532 is being developed as a once-daily treatment for Type 2 diabetes and obesity. In multi-target research cooperation where Pfizer has access to Sosei Heptare's unique StaR (stabilized receptor) technology, Pfizer scientists made the discovery of PF-07081532. The Pfizer-conducted Phase 1 clinical trial for PF-07081532 was successful.
The Growing Awareness And Government Initiatives Are Boosting The Global Oral Anti-Diabetic Drugs Market Growth During The Forecast Period.
The largest diabetes awareness campaign in the world, World Diabetes Day reaches over one billion individuals in more than 160 countries. The primary goal of honoring this day is to raise awareness of diabetes and encourage people to take action to address this major global health concern. Access to Diabetes Care is the focus of World Diabetes Day 2021–23. "Education to Protect Tomorrow" is the focus of the World Diabetes Day 2021–23 campaign's second year.
The emphasis of the campaign 2022 was on the requirement for improved accessibility to high-quality diabetes education for medical professionals and diabetic patients. Activities will emphasize the importance of improving health professionals' and diabetes patients' access to high-quality diabetes education.
Personalized Medicines Provide Oral Anti-Diabetic Drugs Market Growth Opportunities
Rapid developments in data science and technology have the potential to increase the accuracy of therapeutic and preventative interventions and make it possible to recommend the correct treatment to the right patient at the right time. A "one size fits all" strategy is ineffective for treating type 2 diabetes since it is a complex, heterogeneous, and polygenic palette of metabolic diseases.
The efficient analysis of thousands of genes, proteins, and metabolites is now possible due to technological advancements in genetics, genomics, proteomics, and metabolomics. This presents new opportunities for identifying genetic factors and gene products that are linked to various subtypes of diseases, such as diabetes mellitus.
COVID-19 Impact Analysis
The COVID-19 pandemic has had a significant impact on the oral anti-diabetic drugs market. Patient behavior has changed as a result of COVID-19, including a decrease in visits to medical facilities and an increase in reliance on remote healthcare services. The demand for these medications may have been impacted because some diabetics may have had trouble getting access to oral anti-diabetes medications or sticking to their treatment plans.
As of 2023, the COVID-19 situation is recovering and all healthcare facilities are accessible for patients and can give proper treatment leading o increasing demand for oral anti-diabetic drugs worldwide.
Russia-Ukraine Conflict Analysis
The impact of the Russia-Ukraine war on the oral anti-diabetic drugs market is complex and multifaceted. Population displacement may occur as a result of the conflict because people may be compelled to evacuate their homes or seek safety elsewhere. Access to healthcare services, especially oral diabetes medications, is difficult for displaced people, which could interrupt the management of their diabetes. Both Russia and Ukraine have had negative economic impacts from the conflict. The pricing and availability of oral anti-diabetes medications for both individuals and healthcare systems are impacted by economic instability, currency fluctuations, and inflationary pressures.
Segment Analysis
The global oral anti-diabetic drugs market is segmented based on drug class, dosage type, distribution channel, and region.
The Dopamine -D2 Receptor Agonist Segment Is Expected To Hold A Position In The Market Over The Forecast Period.
The Dopamine -D2 receptor agonist segment accounted for 26.5% market share in the Oral Anti-Diabetic Drugs market in 2022. The research provides insights into the exact mechanism by which bromocriptine mesylate enhances glycemic control. However, it has been demonstrated that bromocriptine mesylate treatment in the morning improves glycemic control in T2D patients without raising plasma insulin concentrations.
This might be connected to the diurnal peak in central dopaminergic tone brought on by morning administration of the quick-release bromocriptine formulation in the brain regions that control peripheral fuel metabolism (including glucose, lipid metabolism, and protein metabolism).
Geographical Analysis
Increasing Collaborations And Partnerships Among The Key Players And Increasing Product Launches Dominate the Asia Pacific Region.
Asia Pacific is expected to dominate the oral anti-diabetic drugs market, accounting for around 24.4% of this market. For instance, in January 2022, earlier exclusively available as injections anti-diabetic medication has now been made available orally by Novo Nordisk India. The company reported that the new medication can help adults with type-2 diabetes better regulate their weight and blood sugar levels.
A naturally occurring hormone called glucagon-like peptide 1 is crucial in preserving the proper level of blood glucose. The only problem with peptide and protein-based biological treatments is that they must be administered intravenously, despite the fact that they are often quite successful.
Competitive Landscape
The major global players in the market include Glenmark Pharma, Abbott, Biocon, Sanofi S.A., Sunpharma, Novartis, Novo Nordisk, Merck, GlaxoSmithKline, and Bristol-Myers Squibb among others.
Why Purchase the Report?
• To visualize the global oral anti-diabetic drugs market segmentation based on the drug class, dosage type, distribution channel, and region and understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of oral anti-diabetic drugs market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as Excel consisting of key products of all the major players.
The global oral anti-diabetic drugs market report would provide approximately 62 tables, 61 figures, and 195 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Drug Class
3.2. Snippet by Dosage Type
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. Increasing prevalence of diabetes
4.1.2. Restraints
4.1.2.1. Side effects associated with diabetic drugs
4.1.3. Opportunity
4.1.3.1. Technological advancements
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's 5 Forces Analysis
5.2. Supply Chain Analysis
5.3. Unmet Needs
5.4. Regulatory Analysis
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID-19
6.1.2. Scenario During COVID-19
6.1.3. Scenario Post COVID-19
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During the Pandemic
6.5. Manufacturers’ Strategic Initiatives
6.6. Conclusion
7. Russia-Ukraine War Analysis
8. Artificial Intelligence Analysis
9. By Product
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
9.1.2. Market Attractiveness Index, By Product
9.1.3. Biguanides*
9.1.4. Introduction
9.1.5. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.1.5.1. Metformin
9.1.6. Alpha-glucosidase inhibitors
9.1.7. Dopamine -D2 Receptor Agonist
9.1.7.1. Bromocriptin (Cycloset)
9.1.7.2. Sodium-glucose Cotransport -2 (SGLT-2) inhibitor
9.1.7.3. Invokana (Canagliflozin)
9.1.7.4. Jardiance (Empagliflozin)
9.1.7.5. Farxiga/Forxiga (Dapagliflozin)
9.1.7.6. Suglat (Ipragliflozin)
9.1.8. Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors
9.1.8.1. Januvia (Sitagliptin)
9.1.8.2. Onglyza (Saxagliptin)
9.1.8.3. Tradjenta (Linagliptin)
9.1.8.4. Vipidia/Nesina (Alogliptin)
9.1.8.5. Galvus (Vildagliptin)
9.1.9. Sulfonylureas
9.1.10. Meglitinides
10. By Dosage Type
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
10.1.2. Market Attractiveness Index, By Dosage Type
10.2. Liquid*
10.2.1. Introduction
10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Capsule
10.4. Tablet
11. By Distribution Channel
11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11.1.2. Market Attractiveness Index, By Distribution Channel
11.2. Hospital Pharmacies*
11.2.1. Introduction
11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
11.3. Retail Pharmacies
11.4. Online Pharmacies
12. By Region
12.1. Introduction
12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
12.1.2. Market Attractiveness Index, By Region
12.2. North America
12.2.1. Introduction
12.2.2. Key Region-Specific Dynamics
12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.2.6.1. The U.S.
12.2.6.2. Canada
12.2.6.3. Mexico
12.3. Europe
12.3.1. Introduction
12.3.2. Key Region-Specific Dynamics
12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.3.6.1. Germany
12.3.6.2. The U.K.
12.3.6.3. France
12.3.6.4. Italy
12.3.6.5. Spain
12.3.6.6. Rest of Europe
12.4. South America
12.4.1. Introduction
12.4.2. Key Region-Specific Dynamics
12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.4.6.1. Brazil
12.4.6.2. Argentina
12.4.6.3. Rest of South America
12.5. Asia-Pacific
12.5.1. Introduction
12.5.2. Key Region-Specific Dynamics
12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
12.5.6.1. China
12.5.6.2. India
12.5.6.3. Japan
12.5.6.4. Australia
12.5.6.5. Rest of Asia-Pacific
12.6. Middle East and Africa
12.6.1. Introduction
12.6.2. Key Region-Specific Dynamics
12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Dosage Type
12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
13. Competitive Landscape
13.1. Competitive Scenario
13.2. Product Benchmarking
13.3. Company Share Analysis
13.4. Key Developments and Strategies
14. Company Profiles
14.1. Glenmark Pharma*
14.1.1. Company Overview
14.1.2. Product Portfolio and Description
14.1.3. Financial Overview
14.1.4. Key Developments
14.2. Abbott
14.3. Biocon
14.4. Sanofi
14.5. Sunpharma
14.6. Novartis
14.7. Novo Nordisk
14.8. Merck
14.9. GlaxoSmithKline
14.10. Bristol-Myers Squibb
LIST NOT EXHAUSTIVE
15. Appendix
15.1. About Us and Services
15.2. Contact Us

언급된 주요 기업들

Glenmark Pharma, 4.	Key Developments, Abbott, Biocon, Sanofi, Sunpharma, Novartis, Novo Nordisk, Merck, GlaxoSmithKline, Bristol-Myers Squibb

표 목록 (Tables)

List of Tables

Table 1 Global Oral Anti-Diabetes Drugs Market Value, By Drug Class, 2022, 2026 & 2030 (US$ Billion)

Table 2 Global Oral Anti-Diabetes Drugs Market Value, By Dosage Type, 2022, 2026 & 2030 (US$ Billion)

Table 3 Global Oral Anti-Diabetes Drugs Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Billion)

Table 4 Global Oral Anti-Diabetes Drugs Market Value, By 0, 2022, 2026 & 2030 (US$ Billion)

Table 5 Global Oral Anti-Diabetes Drugs Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)

Table 6 Global Oral Anti-Diabetes Drugs Market Value, By Drug Class, 2022, 2026 & 2030 (US$ Billion)

Table 7 Global Oral Anti-Diabetes Drugs Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 8 Global Oral Anti-Diabetes Drugs Market Value, By Dosage Type, 2022, 2026 & 2030 (US$ Billion)

Table 9 Global Oral Anti-Diabetes Drugs Market Value, By Dosage Type, 2021-2030 (US$ Billion)

Table 10 Global Oral Anti-Diabetes Drugs Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Billion)

Table 11 Global Oral Anti-Diabetes Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 12 Global Oral Anti-Diabetes Drugs Market Value, By Region, 2022, 2026 & 2030 (US$ Billion)

Table 13 Global Oral Anti-Diabetes Drugs Market Value, By Region, 2021-2030 (US$ Billion)

Table 14 North America Oral Anti-Diabetes Drugs Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 15 North America Oral Anti-Diabetes Drugs Market Value, By Dosage Type, 2021-2030 (US$ Billion)

Table 16 North America Oral Anti-Diabetes Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 17 North America Oral Anti-Diabetes Drugs Market Value, By Country, 2021-2030 (US$ Billion)

Table 18 South America Oral Anti-Diabetes Drugs Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 19 South America Oral Anti-Diabetes Drugs Market Value, By Dosage Type, 2021-2030 (US$ Billion)

Table 20 South America Oral Anti-Diabetes Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 21 South America Oral Anti-Diabetes Drugs Market Value, By Country, 2021-2030 (US$ Billion)

Table 22 Europe Oral Anti-Diabetes Drugs Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 23 Europe Oral Anti-Diabetes Drugs Market Value, By Dosage Type, 2021-2030 (US$ Billion)

Table 24 Europe Oral Anti-Diabetes Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 25 Europe Oral Anti-Diabetes Drugs Market Value, By Country, 2021-2030 (US$ Billion)

Table 26 Asia-Pacific Oral Anti-Diabetes Drugs Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 27 Asia-Pacific Oral Anti-Diabetes Drugs Market Value, By Dosage Type, 2021-2030 (US$ Billion)

Table 28 Asia-Pacific Oral Anti-Diabetes Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 29 Asia-Pacific Oral Anti-Diabetes Drugs Market Value, By Country, 2021-2030 (US$ Billion)

Table 30 Middle East & Africa Oral Anti-Diabetes Drugs Market Value, By Drug Class, 2021-2030 (US$ Billion)

Table 31 Middle East & Africa Oral Anti-Diabetes Drugs Market Value, By Dosage Type, 2021-2030 (US$ Billion)

Table 32 Middle East & Africa Oral Anti-Diabetes Drugs Market Value, By Distribution Channel, 2021-2030 (US$ Billion)

Table 33 Glenmark Pharma: Overview

Table 34 Glenmark Pharma: Product Portfolio

Table 35 Glenmark Pharma: Key Developments

Table 36 Abbott: Overview

Table 37 Abbott: Product Portfolio

Table 38 Abbott: Key Developments

Table 39 Biocon: Overview

Table 40 Biocon: Product Portfolio

Table 41 Biocon: Key Developments

Table 42 Sanofi: Overview

Table 43 Sanofi: Product Portfolio

Table 44 Sanofi: Key Developments

Table 45 Sunpharma: Overview

Table 46 Sunpharma: Product Portfolio

Table 47 Sunpharma: Key Developments

Table 48 Novartis: Overview

Table 49 Novartis: Product Portfolio

Table 50 Novartis: Key Developments

Table 51 Novo Nordisk: Overview

Table 52 Novo Nordisk: Product Portfolio

Table 53 Novo Nordisk: Key Developments

Table 54 Merck: Overview

Table 55 Merck: Product Portfolio

Table 56 Merck: Key Developments

Table 57 GlaxoSmithKline: Overview

Table 58 GlaxoSmithKline: Product Portfolio

Table 59 GlaxoSmithKline: Key Developments

Table 60 Bristol-Myers Squibb: Overview

Table 61 Bristol-Myers Squibb: Product Portfolio

Table 62 Bristol-Myers Squibb: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Oral Anti-Diabetes Drugs Market Value, 2021-2030 (US$ Billion)

Figure 2 Global Oral Anti-Diabetes Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 3 Global Oral Anti-Diabetes Drugs Market Share, By Dosage Type, 2022 & 2030 (%)

Figure 4 Global Oral Anti-Diabetes Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 5 Global Oral Anti-Diabetes Drugs Market Share, By Region, 2022 & 2030 (%)

Figure 6 Global Oral Anti-Diabetes Drugs Market Y-o-Y Growth, By Drug Class, 2022-2030 (%)

Figure 7 Biguanides Oral Anti-Diabetes Drugs Market Value, 2021-2030 (US$ Billion)

Figure 8 Alpha-glucosidase Inhibitors Oral Anti-Diabetes Drugs Market Value, 2021-2030 (US$ Billion)

Figure 9 Dopamine -D2 Receptor Agonist Oral Anti-Diabetes Drugs Market Value, 2021-2030 (US$ Billion)

Figure 10 Sodium-glucose Cotransport -2 (SGLT-2) inhibitor Oral Anti-Diabetes Drugs Market Value, 2021-2030 (US$ Billion)

Figure 11 Dipeptidyl Peptidase - 4 (DPP-4) Inhibitors Oral Anti-Diabetes Drugs Market Value, 2021-2030 (US$ Billion)

Figure 12 Sulfonylureas Oral Anti-Diabetes Drugs Market Value, 2021-2030 (US$ Billion)

Figure 13 Meglitinides Oral Anti-Diabetes Drugs Market Value, 2021-2030 (US$ Billion)

Figure 14 Global Oral Anti-Diabetes Drugs Market Y-o-Y Growth, By Dosage Type, 2022-2030 (%)

Figure 15 Liquid Dosage Type in Global Oral Anti-Diabetes Drugs Market Value, 2021-2030 (US$ Billion)

Figure 16 Capsule Dosage Type in Global Oral Anti-Diabetes Drugs Market Value, 2021-2030 (US$ Billion)

Figure 17 Tablet Dosage Type in Global Oral Anti-Diabetes Drugs Market Value, 2021-2030 (US$ Billion)

Figure 18 Global Oral Anti-Diabetes Drugs Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 19 Hospital Pharmacies Distribution Channel in Global Oral Anti-Diabetes Drugs Market Value, 2021-2030 (US$ Billion)

Figure 20 Retail Pharmacies Distribution Channel in Global Oral Anti-Diabetes Drugs Market Value, 2021-2030 (US$ Billion)

Figure 21 Online Pharmacies Distribution Channel in Global Oral Anti-Diabetes Drugs Market Value, 2021-2030 (US$ Billion)

Figure 22 Global Oral Anti-Diabetes Drugs Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 23 North America Oral Anti-Diabetes Drugs Market Value, 2021-2030 (US$ Billion)

Figure 24 Asia-Pacific Oral Anti-Diabetes Drugs Market Value, 2021-2030 (US$ Billion)

Figure 25 Europe Oral Anti-Diabetes Drugs Market Value, 2021-2030 (US$ Billion)

Figure 26 South America Oral Anti-Diabetes Drugs Market Value, 2021-2030 (US$ Billion)

Figure 27 Middle East and Africa Oral Anti-Diabetes Drugs Market Value, 2021-2030 (US$ Billion)

Figure 28 North America Oral Anti-Diabetes Drugs Market Value, 2021-2030 (US$ Billion)

Figure 29 North America Oral Anti-Diabetes Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 30 North America Oral Anti-Diabetes Drugs Market Share, By Dosage Type, 2022 & 2030 (%)

Figure 31 North America Oral Anti-Diabetes Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 32 North America Oral Anti-Diabetes Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 33 South America Oral Anti-Diabetes Drugs Market Value, 2021-2030 (US$ Billion)

Figure 34 South America Oral Anti-Diabetes Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 35 South America Oral Anti-Diabetes Drugs Market Share, By Dosage Type, 2022 & 2030 (%)

Figure 36 South America Oral Anti-Diabetes Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 37 South America Oral Anti-Diabetes Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 38 Europe Oral Anti-Diabetes Drugs Market Value, 2021-2030 (US$ Billion)

Figure 39 Europe Oral Anti-Diabetes Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 40 Europe Oral Anti-Diabetes Drugs Market Share, By Dosage Type, 2022 & 2030 (%)

Figure 41 Europe Oral Anti-Diabetes Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 42 Europe Oral Anti-Diabetes Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 43 Asia-Pacific Oral Anti-Diabetes Drugs Market Value, 2021-2030 (US$ Billion)

Figure 44 Asia-Pacific Oral Anti-Diabetes Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 45 Asia-Pacific Oral Anti-Diabetes Drugs Market Share, By Dosage Type, 2022 & 2030 (%)

Figure 46 Asia-Pacific Oral Anti-Diabetes Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 47 Asia-Pacific Oral Anti-Diabetes Drugs Market Share, By Country, 2022 & 2030 (%)

Figure 48 Middle East & Africa Oral Anti-Diabetes Drugs Market Value, 2021-2030 (US$ Billion)

Figure 49 Middle East & Africa Oral Anti-Diabetes Drugs Market Share, By Drug Class, 2022 & 2030 (%)

Figure 50 Middle East & Africa Oral Anti-Diabetes Drugs Market Share, By Dosage Type, 2022 & 2030 (%)

Figure 51 Middle East & Africa Oral Anti-Diabetes Drugs Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 52 Glenmark Pharma: Financials

Figure 53 Abbott: Financials

Figure 54 Biocon: Financials

Figure 55 Sanofi: Financials

Figure 56 Sunpharma: Financials

Figure 57 Novartis: Financials

Figure 58 Novo Nordisk: Financials

Figure 59 Merck: Financials

Figure 60 GlaxoSmithKline: Financials

Figure 61 Bristol-Myers Squibb: Financials

세계 경구용 항당뇨제 시장 – 2023-2030

Global Oral Anti-Diabetic Drugs Market - 2023-2030